Altheome
Assay Development & ScreeningProtein Sciences & ReagentsPK/PD & ModelingOncologyHematologySmall MoleculePeptide
Quick answer
Outsourcing a bispecific or multispecific antibody means hiring CRO and CDMO partners for the work generalists struggle with: format engineering and chain pairing, mispairing and aggregation control, developability and immunogenicity screening, and CHO cell-line and process development built for low-abundance, hard-to-purify formats. On BioBridgeX, buyers source and compare vetted suppliers in one place, free for buyers.
Bispecific / Multispecific Antibody CRO and CDMO vendors (68)
UNIQ Trials
PK/PD & ModelingBioanalytical ServicesIND / Regulatory Package AuthoringOncologyHematologySmall MoleculePeptide
TRiCBIO
Target ID & ValidationAssay Development & ScreeningHit IdentificationOncologyCNS / NeurologySmall MoleculePeptide
VCHP Clinical Solutions
Computational / AI-Driven DiscoveryPK/PD & ModelingPhase 1 / Early Clinical UnitOncologyHematologySmall MoleculePeptide
Synaffix (a Lonza company)
Unclaimed · public records
CDMO · ADC / Bioconjugation, Medicinal & Synthetic Chemistry, Process Development
ADC / BioconjugationMedicinal & Synthetic ChemistryProcess DevelopmentOncologyAntibody-Drug Conjugate (ADC)Bispecific / Multispecific Antibody
WuXi XDC
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Biologics, Drug Substance: Small Molecule / API
ADC / BioconjugationDrug Substance: BiologicsDrug Substance: Small Molecule / APIOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
MabPlex
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Biologics, Cell Line / Strain Development
ADC / BioconjugationDrug Substance: BiologicsCell Line / Strain DevelopmentOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
Catalent
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, Plasmid DNA Manufacturing
Viral Vector ManufacturingCell Therapy ManufacturingPlasmid DNA ManufacturingOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
GenScript ProBio
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Bionova Scientific
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Avid Bioservices
Unclaimed · public records
CDMO · Process Development, Analytical Development, Drug Substance: Biologics
Process DevelopmentAnalytical DevelopmentDrug Substance: BiologicsOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Cytovance Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
ProBioGen
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Just - Evotec Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Wheeler Bio
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Rentschler Biopharma
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
KBI Biopharma
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
AGC Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
FUJIFILM Diosynth Biotechnologies
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Catalent Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Boehringer Ingelheim BioXcellence
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
WuXi Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Samsung Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Thermo Fisher Scientific (Patheon)
Unclaimed · public records
CRO & CDMO · Process Development, Drug Substance: Small Molecule / API, Analytical Development
Process DevelopmentDrug Substance: Small Molecule / APIAnalytical DevelopmentOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Lonza
Unclaimed · public records
CRO & CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Drug Substance: Small Molecule / APIProcess DevelopmentAnalytical DevelopmentOncologyRare / Orphan DiseaseSmall MoleculeAntibody-Drug Conjugate (ADC)
CellCarta
Unclaimed · public records
CRO · Biomarker Discovery & Development, Bioanalytical Services, Immunogenicity & Immunotoxicology
Biomarker Discovery & DevelopmentBioanalytical ServicesImmunogenicity & ImmunotoxicologyOncologyImmunology & InflammationMonoclonal Antibody (mAb)Protein / Enzyme (Recombinant)
BioAgilytix Labs
Unclaimed · public records
CRO · Bioanalytical Services, Immunogenicity & Immunotoxicology, Biomarker Discovery & Development
Bioanalytical ServicesImmunogenicity & ImmunotoxicologyBiomarker Discovery & DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Protein / Enzyme (Recombinant)
TD2 (Translational Drug Development)
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, PK/PD & Modeling
In Vitro PharmacologyBiomarker Discovery & DevelopmentPK/PD & ModelingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Biocytogen
Unclaimed · public records
CRO · In Vitro Pharmacology, Target ID & Validation, Biomarker Discovery & Development
In Vitro PharmacologyTarget ID & ValidationBiomarker Discovery & DevelopmentOncologyHematologyMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
ProQinase (Reaction Biology Europe)
Unclaimed · public records
CRO · In Vitro Pharmacology, Assay Development & Screening, Biomarker Discovery & Development
In Vitro PharmacologyAssay Development & ScreeningBiomarker Discovery & DevelopmentOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
XenTech
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, PK/PD & Modeling
In Vitro PharmacologyBiomarker Discovery & DevelopmentPK/PD & ModelingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
EPO Berlin-Buch (Experimental Pharmacology & Oncology)
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, PK/PD & Modeling
In Vitro PharmacologyBiomarker Discovery & DevelopmentPK/PD & ModelingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
WuXi AppTec (WuXi Biology)
Unclaimed · public records
CRO & CDMO · In Vitro Pharmacology, DMPK / ADME, Bioanalytical Services
In Vitro PharmacologyDMPK / ADMEBioanalytical ServicesOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
The Jackson Laboratory (JAX)
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, Target ID & Validation
In Vitro PharmacologyBiomarker Discovery & DevelopmentTarget ID & ValidationOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Twist Bioscience
Unclaimed · public records
CRO · Target ID & Validation, Assay Development & Screening, Hit-to-Lead
Target ID & ValidationAssay Development & ScreeningHit-to-LeadOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Abzena
Unclaimed · public records
CRO & CDMO · Assay Development & Screening, Hit-to-Lead, Lead Optimization
Assay Development & ScreeningHit-to-LeadLead OptimizationOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Adimab
Unclaimed · public records
CRO · Assay Development & Screening, Hit-to-Lead, Lead Optimization
Assay Development & ScreeningHit-to-LeadLead OptimizationOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Aurigene Pharmaceutical Services
Unclaimed · public records
CRO & CDMO · Target ID & Validation, Assay Development & Screening, Hit-to-Lead
Target ID & ValidationAssay Development & ScreeningHit-to-LeadOncologyImmunology & InflammationSmall MoleculeMonoclonal Antibody (mAb)
Syngene International
Unclaimed · public records
CRO & CDMO · GLP Toxicology, Safety Pharmacology, DMPK / ADME
GLP ToxicologySafety PharmacologyDMPK / ADMEOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
IQVIA Laboratories (Q2 Solutions)
Unclaimed · public records
CRO · Bioanalytical Services, Biomarker Discovery & Development, DMPK / ADME
Bioanalytical ServicesBiomarker Discovery & DevelopmentDMPK / ADMEOncologyImmunology & InflammationSmall MoleculeMonoclonal Antibody (mAb)
Oncodesign Services
Unclaimed · public records
CRO · In Vitro Pharmacology, DMPK / ADME, Bioanalytical Services
In Vitro PharmacologyDMPK / ADMEBioanalytical ServicesOncologyImmunology & InflammationSmall MoleculeMonoclonal Antibody (mAb)
BioAgilytix
Unclaimed · public records
CRO · Bioanalytical Services, Immunogenicity & Immunotoxicology, Biomarker Discovery & Development
Bioanalytical ServicesImmunogenicity & ImmunotoxicologyBiomarker Discovery & DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Reaction Biology
Unclaimed · public records
CRO · Assay Development & Screening, In Vitro Pharmacology, Target ID & Validation
Assay Development & ScreeningIn Vitro PharmacologyTarget ID & ValidationOncologyImmunology & InflammationSmall MoleculePROTAC / Targeted Protein Degrader
Champions Oncology
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, Assay Development & Screening
In Vitro PharmacologyBiomarker Discovery & DevelopmentAssay Development & ScreeningOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Crown Bioscience
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, Assay Development & Screening
In Vitro PharmacologyBiomarker Discovery & DevelopmentAssay Development & ScreeningOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
WuXi AppTec
Unclaimed · public records
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
GLP ToxicologySafety PharmacologyGenetic ToxicologyOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Charles River Laboratories
Unclaimed · public records
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
GLP ToxicologySafety PharmacologyGenetic ToxicologyOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Avance Clinical
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Cytel
Unclaimed · public records
CRO · Biostatistics & Statistical Programming, Clinical Data Management, Clinical Operations
Biostatistics & Statistical ProgrammingClinical Data ManagementClinical OperationsOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Precision for Medicine
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
WuXi Clinical
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Tigermed
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Celerion
Unclaimed · public records
CRO · Phase 1 / Early Clinical Unit, Clinical Operations, Bioanalytical Services
Phase 1 / Early Clinical UnitClinical OperationsBioanalytical ServicesOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
ClinChoice
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Novotech
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Premier Research
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Veristat
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Caidya
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Allucent
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
PSI CRO
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Worldwide Clinical Trials
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Syneos Health
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Medpace
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Fortrea
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
PPD (Thermo Fisher Scientific)
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Parexel
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
ICON plc
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
IQVIA
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
What does it take to develop and manufacture a bispecific or multispecific antibody drug?
A bispecific is not just a harder monoclonal. The moment you ask a single molecule to bind two targets, you inherit a stack of problems that a standard mAb program never sees, and most of them surface early. The first is format. Knobs-into-holes, CrossMab, DART, BiTE, DuoBody, common light chain, scaffold-based designs: the format you pick decides your half-life, your manufacturability, and how ugly the purification gets. A supplier who has only ever made conventional IgG1 will hand you a molecule that looks fine on paper and falls apart at scale.
The engineering and discovery work is where specialists earn their fee. Chain mispairing is the signature failure mode: with two heavy chains and two light chains, the cell can assemble the wrong combinations, and you spend months chasing the correct species out of a soup of half-antibodies, homodimers, and mispaired junk. Good groups design for correct pairing up front (engineered interfaces, charge steering, common light chains) rather than purifying the problem away later. Alongside that sits the developability screen no bispecific should skip: aggregation propensity, thermal and colloidal stability, viscosity at high concentration, and immunogenicity risk from the novel junctions you just created. T-cell engagers add their own layer, since cytokine release and the safety pharmacology around it shape the whole preclinical package.
On the CMC and manufacturing side, the gap between a specialist CDMO and a generalist is widest. Expression is harder because the desired species is often a minority of what the CHO cell secretes, so titers that look healthy can hide a low yield of correctly assembled product. Downstream, you need orthogonal purification (affinity capture plus polishing steps that actually resolve mispaired and aggregated forms) and an analytical package that can prove you have the right molecule: mass spec for chain pairing, intact and reduced mass confirmation, charge variant and size-exclusion profiling, and potency assays that read both arms. A CDMO that has run bispecific cell-line development, scaled the purification, and written the comparability and characterization sections before knows where the bodies are buried. A generalist learns on your program, on your timeline.
How do you choose a CRO or CDMO for a bispecific or multispecific antibody?
Fit to the format matters more than the size of the company. A CDMO with deep AAV experience tells you nothing about whether they can make your CrossMab. Ask for work on your specific format and modality, then push past the marketing slide to the people who would actually run your program. Score two or three suppliers against the same written scope using the checklist below, and weight platform fit and analytical depth above headline capacity.
- Relevant platform and track record: real bispecific or multispecific programs in your format family (knobs-into-holes, CrossMab, DART, common light chain, scaffold), not just a generic antibody history. Ask how many reached IND or clinic.
- GxP and analytical capability for this modality: GMP cell-line and process development, plus the analytics that prove chain pairing and purity (LC-MS intact and reduced mass, peptide mapping, charge variants, SEC for aggregates, dual-arm potency). Weak analytics is the most common hidden gap.
- Mispairing and developability control: how they engineer for correct pairing and screen for aggregation, stability, viscosity, and immunogenicity early, rather than discovering a non-developable molecule at the tox-batch stage.
- Capacity and scale: expression titers and correctly-assembled yield for your format, a realistic path from gram-scale tox material to GMP clinical supply, and honest lead times rather than a queue dressed up as availability.
- Regulatory experience: bispecifics drawn IND and IMPD support, comparability and characterization packages, and prior FDA or EMA interactions for this class, including the safety framing for T-cell engagers and cytokine release.
- IP and confidentiality: a CDA before you disclose sequences or format, clear ownership of cell lines and process know-how, and clarity on any platform the supplier licenses in (some bispecific scaffolds carry third-party royalties you inherit).
Frequently asked questions
What is the difference between a CRO and a CDMO for a bispecific antibody program?
A CRO runs research and testing: format and antibody engineering, developability and immunogenicity screening, in vitro and in vivo pharmacology, and GLP toxicology. A CDMO makes the drug substance and product: cell-line development, upstream and downstream process development, GMP manufacturing, and the analytical and stability work that supports it. Many bispecific programs use both, and some larger organizations span the two. The split that matters is research versus making material under GxP, because the manufacturing and analytical demands of a bispecific are where generalists most often fall short.
Why are bispecific antibodies harder to manufacture than monoclonal antibodies?
Three reasons. First, chain mispairing: with two different heavy and light chains, a cell can assemble many wrong combinations, so the correct molecule is often a minority of what gets secreted. Second, purification: separating the right species from mispaired, half, and aggregated forms takes orthogonal downstream steps a standard mAb process does not need. Third, analytics: you have to prove correct chain pairing and dual-target activity, which means mass spec, charge and size variant analysis, and potency assays reading both arms. A CDMO that has solved these before will not relearn them on your dollar.
What analytical methods should a bispecific CDMO have in place?
At minimum: intact and reduced mass by LC-MS to confirm chain pairing and identity, peptide mapping for sequence and post-translational modifications, charge-variant analysis (cIEF or ion-exchange), size-exclusion chromatography for aggregates and fragments, and a potency assay that measures both binding arms rather than one. For T-cell engagers you also want functional cell-based potency tied to the mechanism. Ask to see method qualification and how they would build the comparability package, because the analytical story is what convinces a regulator you made the molecule you claim.
How do I control chain mispairing in a bispecific?
You design for it rather than purify it away. Engineered heavy-chain interfaces (knobs-into-holes and similar), charge steering, and common or shared light-chain approaches push the cell toward correct assembly. CrossMab-style domain crossover fixes light-chain pairing specifically. A capable discovery CRO will choose the pairing strategy alongside the format at the start, and the CDMO then develops a cell line and purification that hold that purity at scale. If a supplier's only answer to mispairing is more polishing chromatography, treat it as a warning sign.
How much does it cost and how long does it take to develop a bispecific antibody?
It varies too much for a single honest number, and any supplier quoting one without seeing your format is guessing. Bispecifics generally cost more and run longer than a comparable mAb because of the added engineering, the harder cell-line and process development, and the deeper analytical work. The biggest swing factors are your format choice, how developable the molecule turns out to be, and whether mispairing and aggregation force rework. Scope cell-line development, process development, the tox batch, and GMP clinical supply as separate milestones with go/no-go gates so cost and timeline stay visible rather than discovered late.
How does BioBridgeX work for sourcing bispecific CRO and CDMO suppliers?
You tell us the service you need, your format and modality, and your indication, and we surface vetted suppliers that fit, ranked by relevance. BioBridgeX acts as the neutral marketplace: you compare quotes and contract directly with multiple suppliers in one place, instead of negotiating each separately. It is free for buyers, with a flat 2% fee charged to the supplier, and the platform covers all indications and modalities, so a bispecific program that also needs ADC conjugation or formulation work can run through the same agreement.
Source Bispecific / Multispecific Antibody work with one contract
Compare transparent quotes from qualified Bispecific / Multispecific Antibody CRO and CDMO vendors, then contract once. Free for buyers.
Compare quotes